View Cart  

FDA Hands Cornerstone’s Low-Sodium Drug a Complete Response, Wants More Clinical Info

A A
The FDA has shot down Cornerstone Therapeutics’ low-sodium drug lixivaptan for both its proposed indications.

To View This Article:

Login

Subscribe To Drug Industry Daily